Clinical Trials Browser

Not yet recruiting × Carcinoma, Non-Small-Cell Lung × Angiogenesis Inhibitors × Clear all

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung